Firi-cel (CRG-022)
-
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
Matthew J Frank et al, Lancet 2024
-
CD22-Directed Car T-Cell Therapy Induces Complete Remissions in CD19-Directed Car–Refractory Large B-Cell Lymphoma
Baird et al, Blood 2021
CRG-023
-
CRG-023, A Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies
ASH 2024
-
CD22-Targeted CAR T Cell Single Cell Multiomic Features Linked To Patient Outcomes In CD19-CAR Resistant Large B Cell Lymphoma
Kramer et al, EHA 2024
-
CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering
Majzner et al, Nature Medicine 2019
